BioMotiv and Atomwise sign AI partnership to transform therapeutic development

This article was originally published here

The organizations will form co-owned, joint development companies (“JDCs”) that will integrate Atomwise’s AI technology and BioMotiv’s deep expertise in preclinical and clinical development to translate innovative academic

The post BioMotiv and Atomwise sign AI partnership to transform therapeutic development appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply